US 12,358,966 B2
Inducible caspases and methods for use
Eric M. Ostertag, San Diego, CA (US); and Devon Shedlock, San Diego, CA (US)
Assigned to Poseida Therapeutics, Inc., San Diego, CA (US)
Filed by Poseida Therapeutics, Inc., San Diego, CA (US)
Filed on Jun. 13, 2023, as Appl. No. 18/333,904.
Application 18/333,904 is a division of application No. 17/830,773, filed on Jun. 2, 2022, granted, now 11,718,656.
Application 17/830,773 is a division of application No. 16/339,710, granted, now 11,377,480, issued on Jul. 5, 2022, previously published as PCT/US2017/055661, filed on Oct. 6, 2017.
Claims priority of provisional application 62/405,184, filed on Oct. 6, 2016.
Prior Publication US 2023/0348553 A1, Nov. 2, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61P 3/00 (2006.01); A61P 17/02 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07K 14/47 (2006.01); C12N 5/0783 (2010.01); C12N 9/50 (2006.01); C12N 15/52 (2006.01)
CPC C07K 14/705 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61P 3/00 (2018.01); A61P 17/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 14/47 (2013.01); C07K 14/4747 (2013.01); C12N 5/0636 (2013.01); C12N 9/50 (2013.01); C12N 15/52 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12Y 304/22036 (2013.01)] 7 Claims
 
1. A method of modifying a cell therapy in a subject in need thereof, comprising administering to the subject (a) a population of T cells comprising an inducible caspase polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 10, and (b) an induction agent.